Christopher Blanchette

1.1k total citations · 1 hit paper
15 papers, 788 citations indexed

About

Christopher Blanchette is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Physiology. According to data from OpenAlex, Christopher Blanchette has authored 15 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 4 papers in Epidemiology and 4 papers in Physiology. Recurrent topics in Christopher Blanchette's work include Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers), Respiratory Support and Mechanisms (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Christopher Blanchette is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers), Respiratory Support and Mechanisms (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Christopher Blanchette collaborates with scholars based in United States, Spain and Hungary. Christopher Blanchette's co-authors include Marsha A. Raebel, David H. Smith, Stanley Xu, Colleen Ross, Susan Shetterly, Thomas Morel, Melissa Roberts, Chris L. Pashos, Steven Simoens and Mondher Toumi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Transfusion.

In The Last Decade

Christopher Blanchette

14 papers receiving 777 citations

Hit Papers

Use of Stabilized Inverse Propensity Scores as Weights to... 2009 2026 2014 2020 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals
    2009 545 citations Stanley Xu, Colleen Ross et al. Value in Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Blanchette United States 11 146 141 122 119 108 15 788
Andrew Toren Canada 6 135 0.9× 131 0.9× 277 2.3× 140 1.2× 72 0.7× 10 840
Yongling Xiao United States 22 91 0.6× 209 1.5× 90 0.7× 121 1.0× 84 0.8× 46 1.2k
C McLeod United Kingdom 16 178 1.2× 72 0.5× 95 0.8× 51 0.4× 123 1.1× 27 835
Oren Levine Canada 9 121 0.8× 255 1.8× 134 1.1× 97 0.8× 293 2.7× 36 849
Min‐Hua Jen United Kingdom 11 141 1.0× 101 0.7× 96 0.8× 60 0.5× 170 1.6× 41 659
Lucie Opatrny Canada 14 84 0.6× 190 1.3× 63 0.5× 45 0.4× 158 1.5× 28 938
Ellen Korol United States 9 160 1.1× 116 0.8× 68 0.6× 102 0.9× 322 3.0× 19 751
Joe Coresh United States 14 142 1.0× 334 2.4× 48 0.4× 247 2.1× 160 1.5× 21 1.2k
Joyce Lii United States 21 90 0.6× 214 1.5× 369 3.0× 163 1.4× 260 2.4× 54 1.6k
Holly Van Houten United States 17 186 1.3× 199 1.4× 118 1.0× 84 0.7× 126 1.2× 31 806

Countries citing papers authored by Christopher Blanchette

Since Specialization
Citations

This map shows the geographic impact of Christopher Blanchette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Blanchette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Blanchette more than expected).

Fields of papers citing papers by Christopher Blanchette

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Blanchette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Blanchette. The network helps show where Christopher Blanchette may publish in the future.

Co-authorship network of co-authors of Christopher Blanchette

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Blanchette. A scholar is included among the top collaborators of Christopher Blanchette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Blanchette. Christopher Blanchette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Viayna, Elisabet, Eric A. Gehrie, & Christopher Blanchette. (2024). Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality. Transfusion. 64(9). 1640–1647. 1 indexed citations
2.
Viayna, Elisabet, Eric A. Gehrie, Christopher Blanchette, et al.. (2022). Red cell alloimmunization is associated with increased health care costs, longer hospitalizations, and higher mortality. Blood Advances. 6(20). 5655–5658. 12 indexed citations
3.
Gehrie, Eric A., Elisabet Viayna, Christopher Blanchette, et al.. (2021). Longer Hospitalizations, Increased Inpatient Mortality and Costs Are Associated with Alloimmunization Among Patients with Myelodysplastic Syndromes. Blood. 138(Supplement 1). 1075–1075.
4.
Nestler-Parr, Sandra, Mondher Toumi, Chris L. Pashos, et al.. (2018). Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health. 21(5). 493–500. 84 indexed citations
5.
Blanchette, Christopher, et al.. (2018). Comorbidities and length of stay in chronic obstructive pulmonary disease patients. COPD Journal of Chronic Obstructive Pulmonary Disease. 15(4). 355–360. 19 indexed citations
6.
Jensen, I., et al.. (2016). Evaluating cost benefits of combination therapies for advanced melanoma. Drugs in Context. 5. 1–14. 20 indexed citations
7.
Wilson, Michele, Steve Offord, Christopher Blanchette, et al.. (2016). Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs in Context. 5. 1–10. 4 indexed citations
8.
Blanchette, Christopher, Anthony P. Nunes, Nancy U. Lin, et al.. (2015). Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function. Drugs in Context. 4. 1–10. 18 indexed citations
9.
Brunelli, Steven M., et al.. (2015). End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases. ClinicoEconomics and Outcomes Research. 65–65. 19 indexed citations
10.
Penrod, John R., Beata Korytowsky, Allison Petrilla, et al.. (2014). Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy.. Journal of Clinical Oncology. 32(15_suppl). 6582–6582. 12 indexed citations
11.
Roberts, Melissa, Douglas W. Mapel, Hans Petersen, Christopher Blanchette, & Sulabha Ramachandran. (2011). Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. Journal of Medical Economics. 14(6). 769–776. 20 indexed citations
12.
Roberts, Melissa, et al.. (2011). Estimating The Burden And Course Of Severe COPD Exacerbations In The U.S. Hispanic Population. A1496–A1496. 2 indexed citations
13.
Dalal, Anand A., Douglas W. Mapel, Melissa Roberts, Hans Petersen, & Christopher Blanchette. (2010). Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. International Journal of COPD. 6. 13–13. 16 indexed citations
14.
Xu, Stanley, Colleen Ross, Marsha A. Raebel, et al.. (2009). Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals. Value in Health. 13(2). 273–277. 545 indexed citations breakdown →
15.
Hussey, Leslie C., Sonya R. Hardin, & Christopher Blanchette. (2002). Outpatient Costs of Medications for Patients with Chronic Heart Failure. American Journal of Critical Care. 11(5). 474–478. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew Toren Breakdown of academic impact, for papers by Yongling Xiao Breakdown of academic impact, for papers by C McLeod Breakdown of academic impact, for papers by Oren Levine Breakdown of academic impact, for papers by Min‐Hua Jen Breakdown of academic impact, for papers by Lucie Opatrny Breakdown of academic impact, for papers by Ellen Korol Breakdown of academic impact, for papers by Joe Coresh Breakdown of academic impact, for papers by Joyce Lii Breakdown of academic impact, for papers by Holly Van Houten
Rankless by CCL
2026